Gail Dutton

Gail Dutton

Gail Dutton has covered the biotech industry since soon after its inception, focusing on the intersection of business and science.

ARTICLES BY GAIL DUTTON

  • Why A Spin-off Is A Win-Win For Big Pharma And Startups
    Why A Spin-off Is A Win-Win For Big Pharma And Startups

    When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.

  • Breaking Free Of Data Silos Demands A Comprehensive Strategy
    Breaking Free Of Data Silos Demands A Comprehensive Strategy

    With a hypercompetitive landscape and growing demands for real world data, companies need a comprehensive, cross-silo, data strategy to uncover unobvious insights and develop new data streams.

  • Pharma Needs A New Business Model
    Pharma Needs A New Business Model

    Pharmas have a decision to make: Are they drug developers, or are they healthcare companies? Whatever the answer, the proliferation of innovative digital solutions is triggering the need for new business models tailored to what companies want to become, rather than what they’ve always been.

  • What The 2018 Tax Reform Law Means For Life Sciences
    What The 2018 Tax Reform Law Means For Life Sciences

    Tax reform means more cash on hand, but major changes for R&D expensing, net operating losses, and executive compensation.

  • Pharma Cybersecurity After NotPetya
    Pharma Cybersecurity After NotPetya

    Not much has changed in pharma cybersecurity since the NotPeyta ransomware attacked Merck last summer. Many biotech execs think they are too small to be targeted. They’re wrong.

  • Crowdfunding Fizzles As VC Soars
    Crowdfunding Fizzles As VC Soars

    When the economy crashed a few years ago, crowdfunding offered startups a possible lifeline. But it arrived too late to be much use. Now that money is flooding back into biotech, companies needn’t clutter cap sheets with scores of non-accredited investors, so equity crowdfunding is nearly a nonstarter.

  • The Missed Opportunity Of Medical Affairs
    The Missed Opportunity Of Medical Affairs

    If you’re not using medical affairs strategically, you’re missing an important opportunity. As the voice of science, these specialists are more than just a support function.

  • 2018 Likely A Banner Year For IPOs
    2018 Likely A Banner Year For IPOs

    2018 will be a good year for IPOs and for financing. Rounds are larger and non-traditional investors are turning to life sciences.

  • Don’t Have A Chief Innovation Officer? Get One … Now
    Don’t Have A Chief Innovation Officer? Get One … Now

    Chief innovation officers (CInOs) are poised to become one of the more important executives in the C-suite in pharma just as they are in other industries.

  • Whistleblower Best Practices
    Whistleblower Best Practices

    At some point in the life of a pharmaceutical company, a whistleblower is likely to come forward with allegations of wrongdoing. The intricacies of marketing alone can create a minefield of potential mistakes. Your best defense begins now.

More From Gail Dutton